Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy, a phase III trial presented at the ESMO 2014 Congress has shown.

The IMPRESS trial is a randomised phase III study that compared continuation of gefitinib in addition to chemotherapy against chemotherapy alone in patients with lung cancer that carried mutations in the EGFR cell surface receptor.

READ FULL ARTICLE Curated publisher From Medical News Today